Clinical Trial

Integrated Cancer Services in Thailand: A Prototype for Excellence

Study acronym: CEICS
Completed
View on ClinicalTrials.gov →
Summary
Cancer is a significant health crisis globally and specifically within Thailand, where it affects more than 122,000 individuals every year and leads to approximately 86,000 deaths. Beyond the physical and emotional toll on patients, the disease creates immense social and economic challenges. In Thailand, cancer treatment costs exceed 26 billion baht (about $800 million USD) annually. Families often face out-of-pocket costs for cancer care that exceed 30% to 40% of their total household income. Furthermore, the aging of Thai society and lifestyle changes-such as "Westernized" diets and sedentary behavior-are expected to drive these numbers even higher. This situation has created an urgent need for new healthcare models that reduce the burden on major hospitals and make care more accessible to the public. The Project Goal: A new model of care to address these challenges: Researchers developed a prototype Center of Excellence in Integrated Cancer Services. The goal was to test whether a specialized cancer unit could be successfully integrated into a local community clinic rather than functioning as a large, separate hospital. The study used Donabedian's model to evaluate quality, focusing on three specific areas: Structure: The physical setting, equipment, and staff. Process: How the services are actually delivered and Outcomes: The results of the care and the satisfaction of those involved. Phase of Development and Implementation The project was a three-year initiative funded by the National Science, Research, and Innovation Fund of Thailand. Phase 1: Focused on the conceptual design of the center. Phase 2: Involved detailed planning and the development of digital information systems. This is at Phase 3: Focused on the actual implementation and testing of the prototype center in Bangkok
Trial Details
NCT Number NCT07600294
Lead Sponsor Chulabhorn Cancer Center
Collaborators: Chulabhorn Royal Academy
Conditions Cancer
Enrollment 358 participants
Start Date 2024-03-02
Primary Completion 2024-07-13 (estimated)
Study Completion 2024-07-13 (estimated)
Updated on ClinicalTrials.gov 2026-05-20